Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human/Mouse/Rat |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-CES3 (269-568) is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:2000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
CES3 |
Gene ID: |
23491 |
Uniprot ID: |
EST3_HUMAN |
Immunogen Region: |
269-568 |
Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 269-568 of human CES3 (NP_001172106.1). |
Immunogen Sequence: |
WPLAQKIANTLACSSSSPAE MVQCLQQKEGEELVLSKKLK NTIYPLTVDGTVFPKSPKEL LKEKPFHSVPFLMGVNNHEF SWLIPRGWGLLDTMEQMSRE DMLAISTPVLTSLDVPPEMM PTVIDEYLGSNSDAQAKCQA FQEFMGDVFINVPTVSFSRY LRDSGSPVFFYEFQHRPSSF AKIKPAWVKADHGAEGAFVF GGPFLMDESSRLEATEEEKQ LSLTMMAQWTHFARTGDPN |
Tissue Specificity | Expressed in liver, colon and small intestine. |
Post Translational Modifications | N-glycosylated. |
Function | Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows low catalytic efficiency for hydrolysis of CPT-11 (7-ethyl-10-4-(1-piperidino)-1-piperidino-carbonyloxycamptothecin), a prodrug for camptothecin used in cancer therapeutics. |
Protein Name | Carboxylesterase 3Liver Carboxylesterase 31 Homolog |
Database Links | Reactome: R-HSA-211945Reactome: R-HSA-8964038 |
Cellular Localisation | Endoplasmic Reticulum Lumen |
Alternative Antibody Names | Anti-Carboxylesterase 3 antibodyAnti-Liver Carboxylesterase 31 Homolog antibodyAnti-CES3 antibodyAnti-UNQ869 antibodyAnti-PRO1887 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance